Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants

Journal of Medical Virology

Volumn 78, Issue 3, 2006, Pages 341-352

  Suzuki, Fumitaka ^a,b   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Sezaki, Hitomi ^a   Arase, Yasuji ^a   Hosaka, Tetsuya ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Matsuda, Marie ^a   Satoh, Junko ^a   Watahiki, Sachiyo ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

Author keywords

Breakthrough hepatitis; HBV; Reverse transcriptase; YMDD mutant

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MEMBRANE PROTEIN; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROTEIN MOTIF; RISK FACTOR; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOME, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; JAPAN; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 33644637056     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20546     Document Type: Article

References (32)

1. Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. 2003. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol 27:111-116.
2. Beasley RP, Hwang LW, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet ii:1129-1233.
3. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. 2002. Selection of hepatitis B virus polymerase mutations with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:264-273.
4. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term Lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
5. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE 4th, Isom H, Bowden S, Desmond P, Locarnini SA. 2003. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35.
6. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P, Locarnini S. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 45:2495-2501.
7. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184:1236-1245.
8. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771-4779.
9. Dienstag JL, Perrilo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
10. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, Condrey LD, Woessner M, Rubin M, Brown NA, the U.S. Lamivudine Investigator Group. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
11. Fu L, Cheng YC. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC(3TC) resistance. Biochem Pharmacol 55:1567-1572.
12. Günther S, Li B-C, Miska S, Krüger DH, Meisel H, Will H. 1995. Anovel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutations in immunosuppressed patients. J Virology 69:5437-5444.
13. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32:847-851.
14. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 37:310-314.
15. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. 2001. Fatal submassive hepatitis necrosis associated with tyrosine-methionine-asparate- asparate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infec Dis 33:403-405.
16. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF, the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of Lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
17. Leung N. 2000. Liver disease-significant improvement with lamivudine. J Med Virol 61:380-385.
18. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
19. Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. 2005. High frequency of functional anti-YMDD and mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 54:152-161.
20. Ling R, Harrison TJ. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 80:601-606.
21. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutations associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
22. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32:1078-1088.
23. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
24. Perrillo RP. 2001. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009-1022.
25. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
26. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30:743-748.
27. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2002. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 37:824-830.
28. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Takagi K, Kumada H. 2003. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 46:182-189.
29. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. 2004. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J Virol 78:8524-8535.
30. Torresi J. 2002b. The virological and clinical significance of mutation in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25:97-106.
31. Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. 2002a. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299:88-99.
32. Zollner B, Stoehr A, Plettenberg A, Feucht H, Schroter M, Schafer P, Laufs R. 2000. In vivo dynamics and pathogenicity of wild-type and resistant hepatitis B virus during long-term lamivudine monotherapy-Clinical note. J Clin Virol 17:183-188.